AQST - Aquestive Therapeutics: Bullish Outlook Continues To Harden

• Aquestive Therapeutics is moving closer to resubmitting Libervant’s NDA. The company expects to submit the NDA by the end of this month, which could put the PDUFA date in 2021.
• Aquestive continues to fight through COVID-19 headwinds and was able to report impressive Q1 numbers with SYMPAZAN recording strong year-over-year growth.
• The company’s epinephrine program continues to move forward with two possible candidates. If approved, the PharmFilm products could disrupt the epinephrine market that is dominated by EpiPen and other IM injections.
• I discuss my plans for managing my AQST position around the NDA and potential approval.

For further details see: